長效注射劑市場：依適應症、分子類型、給藥途徑、器械類型、製劑技術、病患類型、最終用戶、分銷管道、支付方和地區分類

預計到 2025 年，長效注射劑市場規模將達到 191.6 億美元，到 2032 年將達到 453.6 億美元，2025 年至 2032 年的複合年成長率為 13.1%。

全球長效注射劑（緩釋注射劑）市場是製藥業中一個快速發展的細分領域，其特點是採用創新的藥物遞送系統，旨在提高患者依從性和治療效果。長效注射劑（LAI）是一種特殊配方，可透過肌肉注射、皮下注射或其他注射途徑給藥，可在數週至數月的較長時間內持續釋放藥物。這些先進的藥物傳遞機制無需頻繁給藥，從而解決了與藥物依從性相關的重大挑戰，尤其是在思覺失調症、雙相情感障礙、糖尿病和愛滋病治療等慢性疾病中。

該市場涵蓋多種技術平台，包括微球、脂質體、植入和緩釋製劑，利用先進的藥物傳遞技術實現可控且持續的治療效果。慢性病發病率的上升、對以患者為中心的醫療保健解決方案的日益重視以及對個性化醫療需求的成長，正推動著長效注射劑（LAI）研發領域的大量投資。製藥公司日益認知到緩釋製劑的商業性潛力，它可以透過改善患者療效、降低醫療成本和增強市場差異化來提供競爭優勢。複雜的生產流程、嚴格的監管要求和大量的研發投入，使得緩釋製劑成為多種疾病領域現代治療策略的關鍵組成部分。

市場動態

全球長效注射劑市場由多個關鍵促進因素推動，這些因素正在從根本上改變藥物治療模式和患者照護方法。其中一個關鍵成長要素源自於解決藥物依從性差這項重大挑戰的需求。藥物依從性差影響約40-60%的慢性疾病患者，導致數十億美元的醫療成本增加和治療效果下降。長效注射劑透過持續給藥，無需每日給藥，提供了強烈的解決方案，這對精神疾病、糖尿病和感染疾病患者尤其有利。慢性病盛行率的上升、全球人口老化以及人們對個人化醫療日益成長的認知，都為長效注射劑生產商創造了巨大的市場機會。

然而，該市場面臨著許多限制因素，包括高昂的研發成本、複雜的生產流程以及嚴格的監管核准流程，這些都可能將研發週期延長數年。此外，製劑穩定性、注射部位反應和劑量柔軟性等方面的技術挑戰也阻礙了市場擴張。

此外，與口服藥物相比，長效注射劑（LAI）較高的初始治療費用以及醫師對LAI給藥技術的不熟悉程度也可能阻礙其推廣應用。儘管存在這些挑戰，但隨著藥物遞送系統技術的進步、應用範圍的拓展以及醫療專業人員對基於價值的醫療模式日益重視，市場仍蘊藏著巨大的機會。可生物分解聚合物、奈米技術遞送系統和聯合治療的出現，正在為市場成長開闢新的途徑；同時，新興市場投資的增加和醫療基礎設施的改善，也為行業相關人員開闢了新的收入來源。

本報告的主要特點

• 本報告對全球長效注射劑市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
• 它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
• 根據公司概況、產品系列、主要亮點、財務表現和策略等參數，對全球長效注射劑市場的主要企業進行了分析。
• 本報告提供的見解將使負責人和企業經營團隊能夠就未來的產品發布、合作關係、市場擴張和行銷策略做出明智的決策。
• 《全球長效注射劑市場》報告面向該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過各種策略矩陣來分析全球長效注射劑市場，從而更輕鬆地做出決策。

目錄

第1章 分析目標和先決條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監理及趨勢分析

• 市場動態
• 促進要素
• 抑制因素
• 機會
• 影響分析
• 重大進展
• 監管情景
• 產品上市/核准
• PEST分析
• 波特五力分析
• 企業合併情景
• 產業趨勢

4. 全球長效注射劑市場（依適應症分類）（2020-2032 年）

• 精神疾病
• 神經系統疾病
• 內分泌和代謝紊亂
• 感染疾病
• 女性健康
• 腫瘤科和支持性治療
• 疼痛、成癮和中樞神經系統支持性護理
• 其他慢性疾病

5. 全球長效注射劑市場（依分子類型分類）（2020-2032 年）

• 小分子藥物
• 胜肽和胜肽類似物
• 蛋白質和生物製藥
• 基於核酸的基因修飾劑
• LAI型疫苗/免疫療法
• 其他分子類型

6. 全球長效注射劑市場依給藥途徑分類（2020-2032 年）

• 肌肉內注射（IM）
• 皮下（SC）
• 玻璃體內注射
• 關節內
• 鞘內/硬膜外
• 其他特殊腸外給藥途徑

7. 全球長效注射劑市場（依器材類型分類）（2020-2032 年）

• 預填充式注射器
• 自動注射器
• 管瓶和注射器套裝
• 植入套件
• 長效注射筆系統

8. 全球長效注射劑市場依製劑技術分類（2020-2032 年）

• 基於微球的儲庫
• 原位成型倉庫
• 脂質體配方
• 奈米懸浮液
• 聚合物結合長效注射劑
• 植入式長效注射裝置
• 油基注射庫
• 長效注射用結晶質懸浮液

9. 全球長效注射劑市場（依病患類型分類）（2020-2032 年）

• 成人
• 老年人
• 兒童

第10章 全球長效注射劑市場（依最終用戶分類）（2020-2032 年）

• 醫院
• 專科診所
• 社區醫療中心
• 門診手術中心
• 居家醫療/自我管理計劃
• 政府和公共衛生項目

第11章 全球長效注射劑市場依通路分類（2020-2032 年）

• 零售藥房
• 醫院藥房
• 網路藥房

12. 全球長效注射劑市場（依支付方分類）（2020-2032 年）

• 公共機構
• 私人的

第13章 全球長效注射劑市場（按地區分類）（2020-2032 年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
• 非洲
  • 南非
  • 北非
  • 中非

第14章 競爭格局

• Eli Lilly and Company
• Novo Nordisk A/S
• Janssen Pharmaceuticals（Johnson and Johnson）
• AstraZeneca
• Pfizer Inc
• GlaxoSmithKline plc
• ViiV Healthcare
• Merck and Co Inc
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Boehringer Ingelheim
• Amgen Inc
• Roche
• Sun Pharmaceutical Industries

第15章 分析師建議

• 機會
• 分析師觀點
• Coherent Opportunity Map (COM)

第16章 參考文獻與分析方法

• 參考
• 分析方法
• 關於 Coherent Market Insights

Long Acting Injectables Market is estimated to be valued at USD 19.16 Bn in 2025 and is expected to reach USD 45.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.1% from 2025 to 2032.

The global long acting injectables market represents a rapidly evolving segment of the pharmaceutical industry, characterized by innovative drug delivery systems designed to enhance patient compliance and therapeutic outcomes. Long acting injectables (LAIs) are specialized pharmaceutical formulations administered via intramuscular, subcutaneous, or other injection routes, providing sustained drug release over extended periods ranging from weeks to months. These advanced delivery mechanisms eliminate the need for frequent dosing, addressing critical challenges associated with medication adherence, particularly in chronic conditions such as schizophrenia, bipolar disorder, diabetes, and HIV treatment.

The market encompasses various technological platforms including microspheres, liposomes, implants, and depot formulations, utilizing sophisticated drug delivery technologies to achieve controlled and sustained therapeutic effects. The growing prevalence of chronic diseases, increasing focus on patient-centric healthcare solutions, and rising demand for personalized medicine are driving significant investments in LAI research and development. Pharmaceutical companies are increasingly recognizing the commercial potential of long acting formulations, as they offer competitive advantages through improved patient outcomes, reduced healthcare costs, and enhanced market differentiation. The market landscape is characterized by complex manufacturing processes, stringent regulatory requirements, and substantial research and development investments, positioning LAIs as a critical component of modern therapeutic strategies across multiple disease areas.

Market Dynamics

The global long acting injectables market is propelled by several key drivers that are fundamentally reshaping pharmaceutical treatment paradigms and patient care approaches. The primary growth driver stems from the critical need to address medication non-adherence, which affects approximately 40-60% of patients with chronic conditions, resulting in billions of dollars in healthcare costs and compromised therapeutic outcomes. Long acting injectables offer a compelling solution by ensuring consistent drug delivery and eliminating daily dosing requirements, particularly benefiting patients with psychiatric disorders, diabetes, and infectious diseases. The increasing prevalence of chronic diseases, aging global population, and growing awareness of personalized medicine are creating substantial market opportunities for LAI manufacturers.

However, the market faces significant restraints including high development costs, complex manufacturing processes, and stringent regulatory approval pathways that can extend development timelines by several years. The technical challenges associated with formulation stability, injection site reactions, and dose flexibility limitations also present barriers to market expansion.

Additionally, higher initial treatment costs compared to oral medications and limited physician familiarity with LAI administration techniques can impede adoption rates. Despite these challenges, the market presents remarkable opportunities through technological advancements in drug delivery systems, expanding applications across therapeutic areas, and increasing healthcare focus on value-based care models. The emergence of biodegradable polymers, nanotechnology-based delivery systems, and combination therapy approaches are creating new avenues for market growth, while growing investments in emerging markets and increasing healthcare infrastructure development are opening additional revenue streams for industry participants.

Key Features of the Study

• This report provides in-depth analysis of the global long acting injectables market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global long acting injectables market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk A/S, Janssen Pharmaceuticals (Johnson and Johnson), AstraZeneca, Pfizer Inc, GlaxoSmithKline plc, ViiV Healthcare, Merck and Co Inc, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Sanofi, Boehringer Ingelheim, Amgen Inc, Roche, and Sun Pharmaceutical Industries
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global long acting injectables market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global long acting injectables market

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Psychiatric disorders
  • Neurological disorders
  • Endocrine and metabolic disorders
  • Infectious diseases
  • Women's health
  • Oncology and supportive care
  • Pain, addiction and CNS supportive care
  • Other chronic diseases
• Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Small-molecule drugs
  • Antipsychotics
  • Hormonal agents (e.g., contraceptives)
  • Analgesics and addiction therapies
  • Other small-molecule LAIs
  • Peptides and peptide analogues
  • GLP-1 and related incretin mimetics
  • Other therapeutic peptides
  • Proteins and biologics
  • Monoclonal antibodies
  • Fusion proteins and recombinant hormones
  • Long-acting growth factors and cytokines
  • Nucleic acid-based and gene-modifying agents
  • Oligonucleotides
  • Gene therapy-linked depot systems
  • Vaccines and immunotherapies in LAI formats
  • Other molecule types
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Intravitreal
  • Intra-articular
  • Intrathecal and epidural
  • Other specialized parenteral routes
• Device Format Insights (Revenue, USD Bn, 2020 - 2032)
  • Pre-filled Syringes
  • Auto-injectors
  • Vial and Syringe Kits
  • Implant Kits
  • Pen-injector LAI Systems
• Formulation Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Microsphere-based Depots
  • In-situ Forming Depots
  • Liposomal LAIs
  • Nano-suspensions
  • Polymer-conjugated LAIs
  • Implantable LAI Devices
  • Oil-based Injectable Depots
  • Long-acting Injectable Crystalline Suspensions
• Patient Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Geriatric
  • Pediatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Community Health Centers
  • Ambulatory Surgical Centers
  • Home-care/Self-administration Programs
  • Government and Public Health Programs
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• Payer Insights (Revenue, USD Bn, 2020 - 2032)
  • Public
  • Private
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Janssen Pharmaceuticals (Johnson and Johnson)
  • AstraZeneca
  • Pfizer Inc
  • GlaxoSmithKline plc
  • ViiV Healthcare
  • Merck and Co Inc
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Boehringer Ingelheim
  • Amgen Inc
  • Roche
  • Sun Pharmaceutical Industries

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Long Acting Injectables Market, By Indication
  • Global Long Acting Injectables Market, By Molecule Type
  • Global Long Acting Injectables Market, By Route of Administration
  • Global Long Acting Injectables Market, By Device Format
  • Global Long Acting Injectables Market, By Formulation Technology
  • Global Long Acting Injectables Market, By Patient Type
  • Global Long Acting Injectables Market, By End User
  • Global Long Acting Injectables Market, By Distribution Channel
  • Global Long Acting Injectables Market, By Payer
  • Global Long Acting Injectables Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Long Acting Injectables Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Psychiatric disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurological disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Endocrine and metabolic disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Infectious diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Women's health
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncology and supportive care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pain, addiction and CNS supportive care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other chronic diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Long Acting Injectables Market, By Molecule Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Small-molecule drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Antipsychotics
    • Hormonal agents (e.g., contraceptives)
    • Analgesics and addiction therapies
    • Other small-molecule LAIs
• Peptides and peptide analogues
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • GLP-1 and related incretin mimetics
    • Other therapeutic peptides
• Proteins and biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Monoclonal antibodies
    • Fusion proteins and recombinant hormones
    • Long-acting growth factors and cytokines
• Nucleic acid-based and gene-modifying agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Oligonucleotides
    • Gene therapy-linked depot systems
• Vaccines and immunotherapies in LAI formats
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other molecule types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Long Acting Injectables Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Intramuscular (IM)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous (SC)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravitreal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intra-articular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intrathecal and epidural
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other specialized parenteral routes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Long Acting Injectables Market, By Device Format, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pre-filled Syringes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Auto-injectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Vial and Syringe Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Implant Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pen-injector LAI Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Long Acting Injectables Market, By Formulation Technology, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Microsphere-based Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• In-situ Forming Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Liposomal LAIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Nano-suspensions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Polymer-conjugated LAIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Implantable LAI Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oil-based Injectable Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Long-acting Injectable Crystalline Suspensions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Long Acting Injectables Market, By Patient Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Long Acting Injectables Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Community Health Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home-care/Self-administration Programs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Government and Public Health Programs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Long Acting Injectables Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Long Acting Injectables Market, By Payer, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Long Acting Injectables Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

14. Competitive Landscape

• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals (Johnson and Johnson)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ViiV Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck and Co Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

15. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

16. References and Research Methodology

• References
• Research Methodology
• About us